Fundraising FoxInomagen Therapeutics
Chicago, US · Founded 2014 · 1 known investors
Find your way into Inomagen Therapeutics
Sign up to see every warm intro you have to Inomagen Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Inomagen Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
Founders & leadership
Inomagen Therapeutics was founded in 2014 by Rishi Arora.
RA
Rishi AroraFounder
GA
Gerard AbateChief Medical Officer
ES
Eric SandbergChief Business OfficerEric Sandberg is Chief Business Officer at Inomagen Therapeutics, a Chicago-based biotech company developing non-viral gene therapy for atrial fibrillation. He holds an MBA and engineering degree and has held commercial leadership roles at medical device and pharmaceutical companies.
Board
MP
Marc PennBoard director
JR
James R. VoglerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$540K disclosed across 3 rounds · 2014–2025
▶$140KraisedJun 2025 · 4 investors · BiotechnologyRule 506(c)
▶$140KraisedJun 2025 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Marc PennDirector
- James R. VoglerDirector
- Offering amount
- $3.8M
- Amount sold
- $140K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$200KraisedApr 2024 · 4 investors · BiotechnologyRule 506(b)
▶$200KraisedApr 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- James R. VoglerDirector
- Marc PennDirector
- Offering amount
- $6.6M
- Amount sold
- $200K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedNov 2014 · 8 investors · BiotechnologyRule 506(b)
▶$200KraisedNov 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
OrogentxOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.
Companies working in the same space as Inomagen Therapeutics.
Frequently asked questions
- What does Inomagen Therapeutics do?
- Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
- Who founded Inomagen Therapeutics?
- Inomagen Therapeutics was founded by Rishi Arora in 2014.
- Who are Inomagen Therapeutics's investors?
- Inomagen Therapeutics's investors include Portal Innovations.
- How much funding has Inomagen Therapeutics raised?
- Inomagen Therapeutics has disclosed $540K raised across 3 rounds.
- Where is Inomagen Therapeutics headquartered?
- Inomagen Therapeutics is headquartered in Chicago, US.